AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,509 AI briefs of material SEC Form 8-K filings by 4,787 companies: 2,123 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,509every one kept
Companies4,787with at least one brief
Recent filings2,123filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Innovative Industrial Properties amended its equity distribution agreements to add its 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program, alongside common stock and 9.00% Series A Preferred Stock. About $336.9 million of the program's $500 million capacity remained available as of the filing date, which gives the company a path to issue more shares that could dilute existing holders.
- Program covers common stock, Series A Preferred Stock and Series B Preferred Stock, with aggregate offering price of up to $500 million
- Approximately $336.9 million remained available for sale under the ATM Prospectus Supplement dated November 9, 2026
- Amendments were entered into November 9, 2026 with BTIG, Piper Sandler, Roth Capital, Stifel, A.G.P./Alliance Global Partners and Huntington Securities
Read the filing on SEC.gov ↗
SS&C Technologies completed a private offering of $1.2 billion of 2.75% convertible senior notes due December 1, 2031, including a $150 million option exercised in full by the initial purchasers. The company plans to use the proceeds for capped call transactions, share repurchases of about $100 million, and redeeming its $2.0 billion of 5.500% Senior Notes due 2027, which adds debt and creates potential dilution if the notes convert.
- Notes issued November 6, 2026 under an indenture with Wilmington Trust, National Association, as trustee, bearing interest at 2.75% payable June 1 and December 1.
- Initial conversion price of about $99.46 per share, a premium of about 25.0% over the $79.57 closing price on November 4, 2026.
- Proceeds planned for about $99 million capped call cost, about $100 million of share repurchases (about 1.3 million shares), and redemption of the $2,000.0 million 2027 Senior Notes.
- Company may not redeem the notes before December 5, 2029, except in a cleanup redemption.
Read the filing on SEC.gov ↗
Jasper Therapeutics announced the results of its offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant, which expired on November 7, 2026. A total of 8,510,658 warrants were properly tendered, about 68.94% of the outstanding warrants, and the company expects to pay $2,757,453.19 in cash for them.
- 8,510,658 warrants were properly tendered and not withdrawn, about 68.94% of outstanding warrants.
- Offer price was $0.324 in cash per warrant, without interest; the offer expired at 12:00 a.m. Eastern Time on November 7, 2026.
- The company expects to pay an aggregate of $2,757,453.19 in cash, to be made promptly.
- The offer was described in a Schedule TO originally filed with the SEC on October 7, 2026.
Read the filing on SEC.gov ↗
In the week of November 2 to November 8, 2026, Strategy reported $283.8 million in net proceeds from sales of its MSTR Class A common stock under its at-the-market program, and used $81.9 million of those proceeds to buy 1,036 bitcoin. It also spent $188.3 million repurchasing STRC preferred stock and held $146.2 million in USD Cash as of November 8.
- MSTR common stock sales: 2,051,348 shares, $283.8 million net proceeds, with $18.3 billion still available for issuance
- Bitcoin: 1,036 bitcoin bought for $81.9 million; aggregate holdings reached 850,364 bitcoin at an average purchase price of $75,456
- STRC preferred repurchases: 1,887,464 shares for $188.3 million; $560.3 million remains under the preferred repurchase program
- USD Reserve stood at $4.77 billion as of November 8, 2026, after $21.1 million was used for preferred dividends
Read the filing on SEC.gov ↗
Atea Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on November 6, 2026, providing for senior secured term loans of up to $200.0 million, with $65.0 million drawn at closing. The loans mature on November 1, 2031, and are secured by substantially all of the company's assets, including its intellectual property, which gives shareholders a larger fixed debt obligation tied to the company's development of BEM/RZR.
- Tranche 1 loan of $65.0 million was drawn on the November 6, 2026 closing date; further tranches total up to $135.0 million
- Interest floats at the greater of the WSJ prime rate plus 2.35% or 9.35%, paid monthly, with interest-only payments for 48 months
- Tranche 2 availability depends on completing the Phase 3 trial of BEM/RZR before a specified date in the second half of 2027
- Financial covenants include a minimum cash test beginning October 1, 2027, and a performance covenant tied to FDA approval of BEM/RZR
Read the filing on SEC.gov ↗
Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.
- Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
- Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
- Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs
Read the filing on SEC.gov ↗
SBA Communications entered a $2.0 billion senior unsecured Term Loan Credit Agreement on November 6, 2026. The company intends to use the $1.165 billion of initial term loans, funded at closing, to repay its Secured Tower Revenue Securities, Series 2021-1C, while $835.0 million of delayed draw commitments remain available until May 6, 2027.
- Total facility of $2.0 billion: $1.165 billion funded on November 6, 2026 and $835.0 million of delayed draw term loan commitments
- Initial term loans will repay the entire $1.165 billion of Secured Tower Revenue Securities, Series 2021-1C
- Term loans mature November 6, 2029, do not amortize and can be prepaid without premium or penalty
- Covenants include a Consolidated Total Net Leverage Ratio not to exceed 7.50 to 1.00 and a Consolidated Senior Secured Leverage Ratio not to exceed 3.50 to 1.00
Read the filing on SEC.gov ↗
FTAI Aviation's subsidiary issued $1.0 billion of 7.125% Senior Notes due November 15, 2034, on November 6, 2026. Net proceeds will repay its revolving credit facility, which was used to fund the parent's accelerated share repurchase program, and redeem $500.0 million of 5.50% notes due 2028.
- Notes: $1.0 billion principal, 7.125% coupon, paid semi-annually, maturing November 15, 2034
- Proceeds: repay in full the Revolving Credit Facility without a reduction in commitments, redeem $500.0 million of 5.50% Senior Notes due 2028, and pay fees
- Notes are senior unsecured, fully guaranteed by FTAI Aviation Ltd., and offered only to qualified institutional buyers and non-U.S. persons
Read the filing on SEC.gov ↗
Valion Bio, Inc. issued 700 Series B Preferred Shares and warrants for 21,539 common shares to investor 3i, LP for $700,000 on November 6, 2026, under a side letter to an earlier agreement. The company also agreed to register the resulting common shares for resale and extended the deadline for further closings to December 9, 2027, which may add future dilution for shareholders.
- Closing purchase price: $700,000 for 700 Series B Preferred Shares and warrants
- Warrants cover 21,539 shares of common stock at an initial exercise price of $0.5182 per share
- Registration statement to be filed within 30 days after closing and declared effective within 60 days
- Outside date for closings under the Series B Preferred Purchase Agreement extended to December 9, 2027
Read the filing on SEC.gov ↗
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
- On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
- Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
- Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
- Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.